Revvity, Inc. (RVTY) Stock Price & Analysis
Revvity, Inc. (RVTY) rose 3.82% to USD 104.13 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
RVTY last closed at USD 100.3; the session ranged USD 101.38–106 on volume of 997,245 shares. Market capitalization is $11.62B, with a 52-week range of USD 81.22–118.3 (NYQ). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 104.13 |
|---|---|
| Change | ▲ 3.82% (up) |
| Previous Close | USD 100.3 |
| Open | USD 101.48 |
| Day Range | USD 101.38 – 106 |
| 52-Week Range | USD 81.22 – 118.3 |
| Volume | 997,245 shares |
| Market Cap | $11.62B |
| Exchange | NYQ |
Technical Analysis (RVTY)
Nexqual's technical model rates RVTY "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.37 (neutral) |
| vs SMA50 | Above (USD 93.76) |
| MACD | 2.34 (positive) |
Analyst Ratings (RVTY)
Wall Street analysts rate RVTY "Buy" based on 14 analysts, with a mean price target of USD 113.64 (range USD 90–145), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 113.64 |
| High Target | USD 145 |
| Low Target | USD 90 |
| Buy / Hold / Sell | 7 / 9 / 0 |
Earnings (RVTY)
| Next Earnings Date | 2026-07-27 |
|---|---|
| EPS Estimate | USD 1.22 |
| Revenue Estimate | $705.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.06 vs est 1.01 ▲ beat |
| 2025-12-31 | USD 1.7 vs est 1.58 ▲ beat |
| 2025-09-30 | USD 1.18 vs est 1.14 ▲ beat |
| 2025-06-30 | USD 1.18 vs est 1.14 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (RVTY)
| Total Revenue | $2.90B |
|---|---|
| Revenue Growth (YoY) | +7.00% |
| Gross Margin | +54.32% |
| Operating Margin | +12.35% |
| Profit Margin | +8.26% |
| ROE | +3.23% |
| Debt / Equity | 46.64 |
| Current Ratio | 1.72 |
| Total Cash | $860.32M |
| Total Debt | $3.35B |
| Free Cash Flow | $508.97M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (RVTY)
Nexqual rates Revvity, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Mixed — Revenue +3.6% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 12% |
| Balance Sheet | Solid — $860M cash vs $3.35B debt |
| Cash Flow | Strong — FCF $509M, 18% margin |
| Efficiency | Weak — ROE 3%, ROA 2.3% |
Ownership (RVTY)
| Insider Ownership | +0.36% |
|---|---|
| Institutional Ownership | +105.81% |
| Shares Outstanding | 111.56M |
| Float | 102.14M |
| Short % of Float | +11.75% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (RVTY)
Revvity, Inc. is led by Prahlad R. Singh (age 60), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| CEO, President & Director | Prahlad R. Singh (age 60) |
|---|---|
| Senior VP & CFO | Maxwell Krakowiak (age 35) |
| Senior Vice President of Global Operations | Tajinder S. Vohra (age 59) |
| Senior VP & Chief Scientific Officer | Madhuri Hegde FACMG |
Major Backers & Investors (RVTY)
Notable institutional backers of Revvity, Inc. include T. Rowe Price, Price (T.Rowe) Associates Inc, Edgepoint Investment Group Inc., according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 35.74% |
| Price (T.Rowe) Associates Inc | 13.28% |
| Edgepoint Investment Group Inc. | 7.89% |
| Janus Henderson Group PLC | 7.48% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 5.04% |
| Victory Capital Management Inc. | 3.02% |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 2.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.95% |
| BlackRock | 6.5% |
| State Street | 3.86% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
From Revvity, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Revvity, Inc. provides health sciences solutions, technologies, and services.
- The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
- Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
- The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EG | Everest Group, Ltd. | USD 331.85 | ▼ 0.77% |
| BALL | Ball Corporation | USD 54.18 | ▲ 2.38% |
| VLTO | Veralto Corp | USD 86.16 | ▲ 0.13% |
| CPAY | Corpay, Inc. | USD 357.84 | ▲ 2.99% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.